BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Saab S, Jimenez M, Fong T, Wu C, Bau S, Jamal Z, Grotts J, Elashoff D. Accessibility to Oral Antiviral Therapy for Patients with Chronic Hepatitis C in the United States. J Clin Transl Hepatol 2016;4:76-82. [PMID: 27350937 DOI: 10.14218/JCTH.2016.00011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Zuckerman A, Carver A, Chastain CA. Building a Hepatitis C Clinical Program: Strategies to Optimize Outcomes. Curr Treat Options Infect Dis. 2018;10:431-446. [PMID: 30524209 DOI: 10.1007/s40506-018-0177-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
2 Vu TM, Toribio W, Riazi F, Ciprian G, Gibbs N, Giardina M, Camacho JA, Parrella K, Cambe J, Amory C, Chasan R, Sigel KM, Weiss JJ. Increasing Access to Hepatitis C Virus Medications: A Program Model Using Patient Navigators and Specialty Pharmacy to Obtain Prior Authorization Approval. J Manag Care Spec Pharm 2018;24:329-33. [PMID: 29578854 DOI: 10.18553/jmcp.2018.24.4.329] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
3 Behrends CN, Eggman AA, Gutkind S, Bresnahan MP, Fluegge K, Laraque F, Litwin AH, Meissner P, Shukla SJ, Perumalswami PV, Weiss J, Wyatt BE, Schackman BR. A Cost Reimbursement Model for Hepatitis C Treatment Care Coordination. J Public Health Manag Pract 2019;25:253-61. [PMID: 29975342 DOI: 10.1097/PHH.0000000000000806] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
4 Millman AJ, Nelson NP, Vellozzi C. Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct Acting Antiviral Era. Curr Epidemiol Rep. 2017;4:174-185. [PMID: 28785531 DOI: 10.1007/s40471-017-0108-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
5 Collins LF, Chan A, Zheng J, Chow SC, Wilder JM, Muir AJ, Naggie S. Direct-Acting Antivirals Improve Access to Care and Cure for Patients With HIV and Chronic HCV Infection. Open Forum Infect Dis 2018;5:ofx264. [PMID: 29308413 DOI: 10.1093/ofid/ofx264] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
6 Paltiel O, Hailu W, Abay Z, Clarfield AM, McKee M. "Sell an Ox" - The Price of Cure for Hepatitis C in Two Countries. Int J Health Policy Manag 2020;9:229-32. [PMID: 32613790 DOI: 10.15171/ijhpm.2019.135] [Reference Citation Analysis]
7 Hsu JC, Wei CF, Yang SC. Effects of removing reimbursement restrictions on targeted therapy accessibility for non-small cell lung cancer treatment in Taiwan: an interrupted time series study. BMJ Open 2019;9:e022293. [PMID: 30878976 DOI: 10.1136/bmjopen-2018-022293] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
8 Wright ZM, Holt BD, Sydlik SA. Covalently-controlled drug delivery via therapeutic methacrylic tissue adhesives. J Mater Chem B 2017;5:7743-55. [DOI: 10.1039/c7tb01151b] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
9 Lynch SM, Wu GY. Hepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy. J Clin Transl Hepatol 2016;4:310-9. [PMID: 28097100 DOI: 10.14218/JCTH.2016.00027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 18] [Article Influence: 0.3] [Reference Citation Analysis]